Increased ribonucleotide reductase (RR) activity has been linked with malignant transformation and tumor cell growth. Therefore, this enzyme is considered t o be an excellent target for cancer chemotherapy. We have examined the effects of a newly patented RR inhibitor, trimidox (3. Among the compounds synthesized as inhibitors of this enzyme, hydroxyurea, a relatively weak inhibitor, is the only clinically used inhibitor of ribonucleotide reductase.
Increased ribonucleotide reductase (RR) activity has been linked with malignant transformation and tumor cell growth. Therefore, this enzyme is considered t o be an excellent target for cancer chemotherapy. We have examined the effects of a newly patented RR inhibitor, trimidox (3. Among the compounds synthesized as inhibitors of this enzyme, hydroxyurea, a relatively weak inhibitor, is the only clinically used inhibitor of ribonucleotide reductase.
Investigators have synthesized various polyhydroxy-substituted benzohydroxamates as inhibitors of ribonucleotide reductase and demonstrated in vitro cytotoxicity and in vivo antitumor activity of some of the compounds.6" One of these agents, didox (3,4-dihydroxybenzohydroxamic acid), has been tested in a clinical phase I studylo." and in women with breast carcinoma."
Another agent, trimidox (3,4,5-trihydroxybenzohydroxamidoxime; Fig 1) inhibits ribonucleotide reductase activity in L1210 cells and exhibits in vitro cytotoxicity and antitumor activity in animals. '3 60 cells with trimidox (25 pmol/L) for 24 hours and then with 10 ymol/L tiazofurin (an inhibitor of inosine monophosphate dehydrogenase) for 4 days produced synergistic growth inhibitory activity, and the cell number decreased t o 16% of untreated controls. When differentiation-linked cell surface marker expressions were determined in cells treated with trimidox and tiazofurin, a significantly increased fluorescence intensity was observed for the CD I l b (2.9-fold), CD 33 (1.9-fold1, and HLA-D cell surface antigens. Expression of the transferrin receptor (CD711 increased 7.3-fold in cells treated with both agents, compared with untreated controls. Our results suggest that trimidox in combination with tiazofurin might be useful in the treatment of leukemia. 0 1994 b y The American Society of Hematology.
We examined the growth inhibitory and cytotoxic effects of trimidox in human promyelocytic leukemia HL-60 cells and tested the effects of trimidox on ribo-and deoxyribonucleoside triphosphate concentrations. In addition, we have studied the effects of trimidox on the cell cycle distribution of HL-60 cells to evaluate its specificity on different phases of cell cycle.
Tiazofurin, an S-phase specific agent, acts through its metabolite, thiazole-4-carboxamide adenine dinucleotide (TAD), an analog of NAD, which inhibits inosine 5"mOnOphosphate (IMP) dehydrogenase activity resulting in depletion of guanylates, including guanosine triphosphate (GTP) and deoxyguanosine triphosphate (dGTP).I4-I6 Tiazofurin down regulates c-myc and Ha-rus oncogene expression and causes differentiation of human leukemia cells.",18 Tiazofurin was shown to be effective in the treatment of patients with refractory chronic granuiocytic leukemia in blast crisis." Both trimidox and tiazofurin are capable of lowering intracellular deoxyribonucleotide levels, although acting through different mechanisms (Fig 2) . We have now examined whether a combination of these agents exhibits synergistic growth inhibitory and cell differentiation properties.
MATERIALS AND METHODS

Drugs.
Didox and Trimidox were synthesized as described,'" and tiazofurin was obtained from the Drug Synthesis and Chemistry Branch, National Cancer Institute (Bethesda, MD).
Cell culture. Human promyelocytic leukemia HL-60 cell line was a gift from Dr R.C. Gallo (National Cancer Institute). CCRF-CEM and Reh human lymphocytic leukemia cells were purchased from the American Type Culture Collection (Rockville, MD). Cells were grown in RPM1 1640 medium supplemented with 10% heat inactivated fetal calf serum (FCS; Grand Island Biological CO, Grand Island, NY) and with 1% penicillin-streptomycin in a humidified atmosphere containing 5% CO,, Cell counts were determined using the microcell counter CC-l08 (Sysmex, Kobe, Japan). Cells growing in logarithmic phase of growth were used for all the studies described below.
Growth inhibition assay. HL-60 cells were seeded in 25-cmZ flasks at a cell density of 1 X 10' cells per milliliter and incubated with various drug concentrations (1-100 pmol/L). Cells were counted and ICso concentrations were determined 4 days later. Flow cytometric analysis of total DNA content and incorporation of bromodeoxyuridine. An aliquot of cells (1 X IO6) was labeled by treatment with 10 pmoVL bromodeoxyuridine (BrdU) for 30 minutes at 37°C. Cells were then centrifuged for 5 minutes at 400g in a Beckman TJ-6 tabletop centrifuge, washed three times with PBS, and fixed in 70% ethanol. Cells were removed from ethanol, resuspended in 1.5 m o a HC1, incubated at 25°C (room temperature) for 20 minutes, and washed with PBS as described.26 An anti-BrdU antibody (20 pL; Becton Dickinson) was added, and the mixture was incubated for 30 minutes at 4°C. followed by incubation for another 30 minutes with 20 pL of fluorochrome FITC-conjugated F(ab'), goat anti-mouse IgG. Finally, the cells were resuspended in 1 mL PBS containing 10 pmoVL propidium iodide (Polyscience, Warrington, PA). Flow cytometric analysis was performed using a FACS 440 system (Becton Dickinson), wherein double-labeled cells were excited at 488 nm. The red fluorescence from propidium iodide was collected through a 620-nm pass filter and recorded as a measure of total DNA content, whereas the green fluorescence from FITC was collected through a 530-nm filter and recorded as a measure of incorporated BrdU. The resulting data were accumulated from a bivariate channel distribution showing the distribution of DNA (red fluorescence) and BrdU (green fluorescence) among the cell population. Routinely, 20,000 cells were analyzed, and the cell cycle distribution was calculated by gating analysis of the bivalent histogram.26
Statistical analysis of synergism. The calculation of dose response curves and determination of synergism were performed using software designed by Chou and Talalay." For and hydroxyurea for 4 days, and the effect on cell growth was determined. Trimidox exhibits an IC5" of 35 pmoVL, whereas didox and hydroxyurea inhibited cell proliferation with IC5,, concentrations of 54 and 73 p r n o a , respectively (Fig 3) . When human leukemia HL-60, CCRF-CEM, or Reh cells were incubated with various concentrations of trimidox for 2 days, ICso of 61 pmol/L, 89 pmoVL, and 104 pmoV L, respectively, were obtained by the MTT assay ( Table 1) . Effect of trimidox on ribonucleoside triphosphate concentration in HL-60 cells. Cells were incubated with 100 pmol/L trimidox for 24 hours, and ribonucleotide levels were analyzed. Trimidox did not significantly alter the concentration of any of the ribonucleotides (data not shown).
RESULTS
Growth inhibitory
Effect of trimidox on deoxynucleoside triphosphate levels in HL-60 cells. HL-60 cells were incubated with 25 or 50 pmol/L trimidox for 24 hours, and the intracellular deoxyribonucleoside triphosphate concentrations were measured as described in Materials and Methods. Treatment with 50 pmol/L trimidox resulted in a significant decrease in intracellular concentrations of deoxycytidine triphosphate (dCTP; 39% of control) and dGTP (24% of control; Table 2 ). The deoxythymidine triphosphate (drTP) level was not significantly changed, whereas intracellular deoxyadenosine triphosphate (dATP) concentration was increased by 25% and 37% of control after incubation with 25 and 50 pmol/L trimidox, respectively. In cells treated with tiazofurin and trimidox, dCTP and dGTP pools decreased below the level of detectability of this assay. Cells were exposed to 5-160 pnol/L concentrations of trimidox for 2 days at 37°C in an atmosphere of 95% air and 5% CO2. MTT assay was then performed according to the method described in Materials and Methods. Effect of trimidox on cell cycle distribution of HL-60 cells. To examine whether trimidox inhibits cell proliferation by blocking the cell cycle transition, HL-60 cells were seeded at a density of 1.0 X lo5 cells per milliliter and incubated with various concentrations (20,40, or 80 pmol/L) of trimidox. After 4 days, cells were harvested and incubated with BrdU as described in Materials and Methods. Cells were labeled with FITC; and the respective distribution into phases of cell cycle was determined using a FACS-analyzer.
Trimidox incubation had no effect on the distribution of cells into their respective phases of cell cycle (data not shown). As trimidox does not show cell cycle specificity, a combined treatment with cell cycle-specific drugs seemed to be a promising approach. Therefore, we incubated HL-60 cells with trimidox first and then with tiazofurin, an S-phasespecific antimetabolite?8
Influence of combination of trimidox and tiazofurin on the growth of HL-60 cells. After incubation of HL-60 cells with 25 pmol/L trimidox for 24 hours, cells were washed in drug-free medium and incubated with 10 pmoVL tiazofurin for 4 days, and then the cell number was quantitated. Trimidox and tiazofurin each decreased cell proliferation to 55% of untreated control cell proliferation. However, after sequential incubation of HL-60 cells with trimidox first and tiazofurin second, the cell number reduced to 16% of untreated control cell number, indicating synergistic cytotoxicity. Similar synergistic effects were observed with different drug concentrations. Combination index was calculated according to the computer program of Chou and Talalay", and it was below 1 for all combinations tested, indicating synergistic growth inhibition (Table 3) .
Combined effect of trimidox and tiazofurin on cell surface marker expression of HL-60 cells. We examined the effect of cell surface markers on the expression of cell differentiation (granulocyte/monocyte) CD 33, CD l l b , and HLA-D leukocyte surface antigens, as well as on the expression of the transfemn receptor (CD 71) in control cells and in cells treated with either compound alone or in combination. As shown in Fig 4, the expression of cell surface markers significantly increased in cells concurrently incubated with trimidox and tiazofurin. The mean fluorescence intensity of CD 33 increased 1.9-fold, and CD 1 l b showed a 2.9-fold enhancement of fluorescence in cells incubated with both agents compared with control cells. When HLA-D expression was determined, mean fluorescence intensity increased from 52 in control to 92 in cells incubated with both compounds. However, the expression of the transferrin receptor increased 7.3-fold in HL-60 cells after sequential treatment with trimidox and tiazofurin.
DISCUSSION
The activities of ribonucleotide reductase and IMP dehydrogenase were amplified in malignant cell^.^,^ These enzymes were, therefore, suggested to be excellent targets for chem~therapy.~.~
We have examined the effects of a newly patented compound, trimidox, on deoxyribonucleotide pools and on cell cycle specificity. Trimidox inhibited ribonucleotide reductase activity both in vitro and in vivo in L1210 cells and was active against L1210 leukemia in rnice.l3 In this report we demonstrate that trimidox significantly lowers dCTP and dGTP levels in HL-60 cells. Continuous incubation of HL-60 cells with 35 pmol/L Trimidox for 4 days inhibited cell growth to 50% of control cell growth, whereas incubation with concentrations up to 80 pmol/L did not have any effect on the cell cycle distribution of HL-60 cells.
Trimidox was earlier shown to have free radical scavenging capacity and was suggested to be an iron t he la tor.'^ Depletion of intracellular iron increases the number of transferrin receptors, which can explain the upregulation of CD 71 receptor in cells treated with trimidox and tiazofurin." However, addition of 2 mg/mL iron-saturated transferrin could not significantly alter the cytotoxicity of trimidox in HL-60 cells (data not shown), indicating that the iron-chelating capacity may not be mainly responsible for trimidoxexerted growth inhibition of HL-60 cells.
Our finding that trimidox-unlike hydroxyurea-does not show S-phase specificity suggests that trimidox and hydroxyurea should have different mechanisms of action.' This is in line with data of Tihan et al," who showed that didox (a first generation polyhydroxy-substituted benzohydroxamate, which is active against hydroxyurea-resistant L1 210 cells) did not alter the cell cycle phase distribution of L1210 cells. Mann et a13' demonstrated that the MI subunit of ribonucleotide reductase was constitutively expressed in rapidly cycling HL-60 cells and was downregulated in quiescent or differentiated cells. However, as the enzyme inhibitory activity of polyhydroxy-substituted benzohydroxamates seems to correlate with their free radical scavenging capacity," future studies should elucidate trimidox's effect on the enzyme subunits.
Lack of significant cell cycle specificity renders trimidox suitable for sequential combination chemotherapy with a number of anticancer drugs. Cancer cells could be pretreated with trimidox and then exposed to cell cycle-specific agents without antagonizing their effect on cell cycle. We have demonstrated synergistic growth inhibition when HL-60 cells were sequentially treated with trimidox first and tiazofurin, an S-phase specific inhibitor of IMP dehydrogenase, second. Figure 2 shows the biochemical actions of trimidox and tiazofurin on deoxyribonucleotide levels. As stated by J a~k o n ,~~ deoxyribonucleotide pools need to be properly balanced to support DNA synthesis, and Cory and Carter' have suggested that a linear reduction in deoxyribonucleotide levels could produce a sigmoidal decrease in the rate of DNA synthesis. This might explain the synergistic action of trimidox and tiazofurin.
Tiazofurin induces differentiation of human promyelocytic leukemia HL-60 and human myelogenous leukemia K 562 cells; thus, we examined whether the synergistic effects observed with trimidox and tiazofurin might be due to their effect on cell differentiati~n.".'*~~~-~' The expression of differentiation-linked cell surface markers was examined in cells treated with trimidox and tiazofurin. We found a significant increase in CD 33, CD l l b , and HLA-D antigen expression in cells incubated with both agents, compared with untreated controls. These results, at least in part, suggest that the combination of these two compounds could lead to differentiation in HL-60 cells.
In summary, treatment with trimidox in combination with tiazofurin might offer an additional promising option in cancer chemotherapy. cycle 
